NIH R01 · 2024
4D virtual Catheter (4D vCath) for multi-factorial hemodynamics in pulmonary hypertension
SUMMARY: Pulmonary Hypertension (PH) is a severe and life-threatening disease that increases mortality rates by 7-fold. Pulmonary Arterial Hypertension (PAH, WHO Group 1) is the most severe subtype, with a median survival of just three years. PAH must be distinguished from another subtype called Pulmonary Venous Hypertension (PVH, WHO Group 2) because PAH treatments can harm PVH patients. Unfortunately, the current diagnostic and prognostic process for PAH is slow, taking 2-4 years after symptom onset, and relies on a series of costly, inconclusive, noninvasive tests ending with invasive catheterization for conclusive diagnosis. Delays and invasive diagnostics worsen patient suffering and…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.